We have endeavoured to find immunological indications of chronic virus infection in patients with chronic fatigue syndrome (myalgic encephalomyelitis) and to investigate immune responsiveness to viruses in such patients in comparison with normal subjects and patients with muscular dystrophy. Levels of circulating IgM immune complexes were elevated (above the 95% normal control range) in 10 (17%) of58 patients with chronic fatigue syndrome, which was not significantly different from the normal controls or from dystrophy controls (by Mann Whitney U test). Levels of IgG complexes were only increased in 10% of patients.
Introduction
Chronic fatigue syndrome (CFS),12 myalgic encephalomyelitis (ME)3 and post-viral fatigue syndrome4'5 are terms used to describe a state of tiredness and physical and mental fatiguability together with a variety of other variable symptoms for which there is no obvious cause. It has been suggested that the symptoms may be the result of a chronic virus infection that has not been adequately dealt with by the immune system,4-6 thus one of the synonyms (post-viral fatigue syndrome) for the condition. The evidence for this stems from the indication that the start of symptoms often, though by no means always, dates from an acute illness attributed to a virus infection. 6 Investigations ofthe immune system have shown numerous abnormalities4'7 but the most notable feature of these investigations is their inconsistency.7 Many investigators, particularly in North America, have considered the chronic fatigue syndrome to be a consequence of infection with Epstein Barr virus (EBV), but enteroviruses, particularly group B Coxsackie viruses (CBV), have also been suggested to be initiators of the disease process;'6 other infectious agents may also be involved. Evidence for persistence of enterovirus in CFS derives from the detection of CBV IgM antibodies in serum,68 the isolation of enterovirus from the stools,' the detection of circulating enteroviral antigen5 and the presence ofenteroviral RNA in muscle biopsies from patients.9 Among more general indications of disturbed immune function are one report of reduced lymphocyte response to a mitogenic lectin,4 the presence of IgM containing immune complexes in the circulation5 and variations in T helper and T suppressor cell levels in the blood. 4 In general, electrophysiological studies of muscle have revealed little if anything abnormal.
The aim of this study was to investigate patients with CFS, firstly to see whether they have circulating immune complexes, either IgG-or IgMcontaining, which would suggest a continuing immune response and a continuing source of antigen, and, secondly, to look for IgM antibodies to CBV and other viruses which would imply a recent infection or possibly a continuing one with incomplete switching to IgG production. Also, we could see how our patients compare with those of other investigators, who have found some 30% of patients have anti-CBV IgM9 which would be useful for purposes of definition in a disease for which the diagnostic criteria are not precise or universally accepted. Indeed it is highly arguable whether CFS represents a single disease or a syndrome consisting of several symptoms of different origin.
Cell-mediated immune responses are also important in controlling virus infections and an indication of such immunity can be obtained from investigation of the proliferative response to viral antigen of blood lymphocytes in vitro. Therefore we endeavoured to assess the reactivity of patients to CBV by investigation of their lymphoproliferative response to CBV antigen. Finally, we have looked for antibodies to a variety ofcommon pathogens to see whether there is any indication of a recent or continuing viral infection. 
Materials and methods

Patients
Lymphocyte proliferation
When the response to Con A was expressed as the increase in counts compared with unstimulated cultures there was no difference between patient (n = 14) and control (n = 18) cell cultures ( Figure  3) , and indeed the scatter of values looks very similar; if the results were expressed as a stimulation index, a less useful way of expressing Con A stimulation, again there was no difference (data not shown). The way to express the proliferation data with the virus stimulated cultures was more problematical. The proliferative response can be expressed as a simple increase of the counts in the antigen stimulated cultures above the 'control antigen' cultures or, more usually, as a stimulation index, the ratio of counts in the antigen cultures to the 'control antigen' cultures.'5 The 'control antigen' cultures always showed thymidine incorporation above that of completely untreated cultures, and variably so. The increases in counts are shown in Figure 4a , where there is no difference between the patient and control groups, though there is a suggestion of a bimodal nature of the response in the patient group. However, it was thought that, as the Con A response might give an indication of the overall proliferative capacity of the particular cell population under investigation, then we should also express the CBV response in relation to the Con A incremental response ( Figure  5a ). The possible bimodal nature of the responsiveness of the patients' cell cultures that is apparent in the uncorrected increase in counts data (Figure 4a ) disappears when this is done. Then we calculated the stimulation indices (Figure 4b ), and no difference between controls and patients was found, nor was any revealed when the data were corrected in relation to the Con A proliferation (Figure 5b) .
Cultures from a small number of muscular dystrophy patients showed values within the range of the normal and disease cultures described. (Table I) .
Other antibody studies Of 17 muscular dystrophy and 19 CFS patients investigated for antibodies to various respiratory viruses only 1 patient was found to have a significant titre, a dystrophy patient with antibody to Mycoplasma pneumoniae. Four CFS patients had a moderately raised titre to influenza B, 2 patients, 1 CFS and 1 dystrophy had moderately raised titres to influenza A and 1 CFS patient had a moderately raised titre to adenovirus. This frequency and distribution of raised titres which are suggestive of recent infection are as expected of any group of subjects. All these patients were negative for anti-EBV IgM.
Discussion
The viral theory of the chronic fatigue syndrome proposes that there is a persistent infection that leads to the symptoms either by a direct effect of virus on muscle, as can be inferred from the demonstration of CBV RNA in the muscle,9 or indirectly via a systemic effect ofthe response to the virus, which can be exemplified by a similarity between some of the symptoms of CFS and those caused by administration of alpha interferon.'6 Another approach to the symptoms proposes that they are mainly of a psychogenic nature,'7 though quite possibly initiated by a viral infection and the accompanying debility, and that symptoms may then be compounded by 'unfitness' accompanying reduced habitual physical activity.'8 The work of Behan and colleagues4 which revealed different patterns of T lymphocyte subset abnormality in patients of short or long duration of symptoms is compatible with the concept that patients of different duration ofdisease may differ in nature. It could be suggested that symptoms may initially relate to a virus infection, but in some individuals behaviour patterns become established and are maintained after the virus infection has resolved.
The suggestion of a persistent viral infection comes largely from investigations of EBV serology, mostly in the USA, which, however, has given a very unclear picture, 7 and also from investigations of CBV in Britain. A higher incidence of neutralizing antibody to CBV, 22% compared with 9% in controls, was found in patients who had recently presented with chronic fatigue syndrome6 and more recently a higher incidence of IgM anti-CBV was found in patients, 37% compared with 9% in controls, indicating a recent or persistent infection.9 More direct evidence of CBV infection has been provided by obtaining positive cultures of CBV from stools of22% ofpatients compared with 7% of controls.5 Further, it was possible to detect an enteroviral antigen, VP1, common to most that we are looking at different populations of patients, though both we and the London group did not include an infectious onset in our criteria for diagnosis. However, of those with high immune complexes who were assessable for an infectious onset, 5 out of 6 had such an onset. Our finding of an absence of IgM antibody to CBV, in a group of patients at least half of whom had indications of a preceding infection, done in the same laboratory as previous investigations, also suggests a different population of patients, though there are no obvious differences in diagnostic criteria between our patients and those investigated in Glasgow,6 though these patients were probably of short duration of disease.
Duration of disease is very likely to be another factor contributing to variability of results between different groups, as already discussed,4 some groups mainly having patients of short duration of symptoms,6 others having patients with a broad range of duration.5 The incidence of 25% for significant levels of neutralizing antibody to Coxsackieviruses in patients with CFS is similar to previous results,6 where control incidence was 9%, but more recent control studies have found a higher incidence, 25%, in the normal population,'9 which shows the variations that can occur with time even in a normal population.
The finding that there was no difference in the lymphocyte proliferative responsiveness to CBV, again, does not indicate any particular aberration in response to this virus, though the wide variation in response of the control cells to the viral antigen and of all cells to the 'control antigen' makes this a less precise determination than that of antibody or immune complex levels.
In conclusion we have found no evidence of an abnormal cell-mediated immune response to Coxsackie B virus, nor did we find any evidence for a general defect in T cell activity, as indicated by responsiveness to the T cell mitogen Concanavalin A, in patients with the chronic fatigue syndrome. There was no serological evidence for increased incidence of infection with Coxsackievirus or various respiratory viruses, nor was there any overall difference in the incidence of circulating immune complexes in the patients. However, there is probably a considerable heterogeneity among patients with CFS, particularly with regard to duration of disease and the presence or absence of an acute infectious onset. Therefore the finding that there was a small percentage of patients with elevated levels of immune complexes may be important in defining a sub-group of patients.
